BMY: 4.58% Dividend Yield Meets the 2028 Patent Cliff
TradeMates rates Bristol-Myers Squibb at an Investment Score of 63 out of 100 today, with a HOLD verdict. The model sees neither a clear buying case nor a reason to exit: valuation is low at a price-to-earnings ratio of 13.88x (FMP, February 2026), and free cash flow of $12.85B (fiscal 2025) covers the 4.58% dividend yield several times over. That combination rules out a sell rating. At the same time, the model lacks the catalyst for an upgrade, because the major revenue patents expire from 2028.
Key Takeaways
- TradeMates assigns 63/100 points and a HOLD verdict — the valuation pillar supports, the growth pillar weighs.
- The P/E stands at 13.88x (FMP, February 2026), well below the historical pharma sector median of roughly 17x (Yahoo Finance, sector screener 2025).
- Free cash flow reached $12.85B for full-year 2025 (10-K 2025) against a dividend yield of 4.58% (Yahoo Finance, February 2026).
- The 2028 patent cliff affects products that together carry more than a third of group revenue on the model's calculation (10-K 2025, product breakdown).
- The analyst consensus sits mostly between "Hold" and "Buy", with a median price target slightly above the current level (analyst consensus, February 2026).
What Bristol-Myers Squibb Co does
Bristol-Myers Squibb is a research-driven pharmaceutical group focused on oncology, hematology, immunology and cardiovascular disease. The company markets a comparatively small number of large revenue drivers rather than a broad portfolio: Eliquis, Opdivo, Revlimid, Pomalyst and Reblozyl rank among its key revenue sources (10-K 2025). Group revenue came in at roughly $48B in fiscal 2025 (10-K 2025), with next-generation growth products — including Reblozyl, Breyanzi and Camzyos — growing at double-digit rates while older drugs are already declining.
Why TradeMates is paying attention today
The core of the model's rating is a valuation gap: Bristol-Myers Squibb trades at a discount that does not fully reflect current cash generation. The model weighs $12.85B in free cash flow (10-K 2025) against a market capitalisation that, at 13.88x earnings (FMP, February 2026), sits well below the sector median. The 4.58% dividend yield (Yahoo Finance, February 2026) is therefore not endangered by a payout ratio above 100% of earnings, but supported by a cash payout ratio that the model calculates at under 50% of free cash flow.
Second, the balance sheet stands out: deleveraging after the Celgene acquisition is well advanced, which the model reads as greater room for bolt-on deals and buybacks. Third, the patent cliff remains the decisive brake — Eliquis loses US market exclusivity from 2028, affecting a substantial share of group revenue (10-K 2025).
Opportunities from the model's perspective
- Valuation buffer: At 13.88x earnings (FMP, February 2026), the market already prices in a meaningful revenue decline on the model's calculation. Stabilisation in the growth portfolio would be enough to disappoint that assumption.
- Cash flow coverage: $12.85B in free cash flow (10-K 2025) against a dividend burden that, at a 4.58% yield, sits clearly below half of free cash flow — the model sees room for continued dividend increases.
- New product cycles: The growth brands grew at double-digit rates in fiscal 2025 (10-K 2025). The model weights this contribution positively, even though it does not fully offset patent losses from 2028.
Risks from the model's perspective
- 2028 patent cliff: US market exclusivity for Eliquis ends in 2028 (10-K 2025). The model expects revenue and margin pressure weighing on earnings from fiscal 2028.
- Concentration risk: A small number of products carries a large share of revenue (10-K 2025). A single patent loss therefore hits harder than at more diversified competitors.
- Value trap rather than value buffer: A low 13.88x P/E (FMP, February 2026) can look expensive again quickly if earnings estimates fall. The model does not treat the discount as an automatic safety cushion.
What investors could check next
- P/E versus earnings estimates: If the P/E rises at an unchanged share price, consensus estimates have fallen — a signal TradeMates treats as an early warning.
- Free cash flow trend in quarterly filings: Comparing 2026 10-Q figures with the prior-year quarter shows whether the $12.85B from 2025 (10-K 2025) can be sustained.
- Revenue contribution from growth brands: The key question is whether Reblozyl, Breyanzi and Camzyos close the 2028 gap faster than planned (10-K 2025).
- Next earnings date: The first-quarter 2026 report provides the first reliable guidance update after the 2025 annual results.
FAQ
Why is the verdict HOLD rather than Buy?
TradeMates weighs two opposing factors. Valuation at 13.88x earnings (FMP, February 2026) and cash flow coverage of the dividend argue for a Buy. The foreseeable revenue gap from 2028 argues against. The result is 63 out of 100 points — too little for a buy recommendation, too much for a sell.
Is the 4.58% dividend safe from the model's perspective?
The model sees the dividend covered by $12.85B in free cash flow (10-K 2025). The payout ratio sits well below free cash flow on the model's calculation, not merely below book earnings. A risk only arises if cash flow falls faster than the payout is adjusted.
How hard does the 2028 patent cliff hit the model scenario?
The model expects revenue declines for the affected drugs that the growth brands only partly offset (10-K 2025). That is why the score stays in HOLD territory despite the currently attractive valuation.
What would need to change for TradeMates to rate BMY higher?
Two things: faster revenue build from the new product generation than consensus assumes, or a further share price decline that pushes the P/E even further below the sector median. Either would give the valuation pillar more weight in the model.
How does BMY compare with the pharma sector?
At 13.88x earnings (FMP, February 2026), the stock trades below the sector median of roughly 17x (Yahoo Finance, sector screener 2025). The 4.58% dividend yield (Yahoo Finance, February 2026) is above the average of comparable large-cap pharma names.
This is a model analysis, not investment advice. Investments carry risk.